Avantor is a leading global provider of integrated, tailored solutions for the life sciences and advanced technology industries. Strengthened by the recent acquisition of VWR, the Company is a trusted partner to customers and suppliers from discovery to delivery. With operations in more than 30 countries and a diverse portfolio that includes more than four million products, Avantor enables customer success through innovation, cGMP manufacturing and comprehensive service offerings. Collectively, we set science in motion to create a better world.
Children’s National Health System, based in Washington, D.C., has been serving the nation’s children since 1870. Children’s National is #1 for babies and ranked in every specialty evaluated by U.S. News & World Report and has been designated two times as a Magnet® hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers in the D.C. Metropolitan area including the Maryland suburbs and Northern Virginia. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is one of the nation’s top NIH-funded pediatric institutions. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels.
Greater Washington had its second-biggest venture funding year in at least a decade in 2017, with startups across the metro area raking in more than $1.55 billion.
TAI Diagnostics said earlier this week that it had closed a $10 million round of funding and forged a new partnership with United Therapeutics (NASDAQ: UTHR).
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.
In covering the D.C. innovation economy comes the inevitable: funding news. Trust us, there’s a lot of it floating around the D.C. metro area. Here’s a roundup of all of the major funding news from the region in December:
Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two new members to their Board of Directors for a term of three years. The election took place on December 14, 2017 at the Virginia Bio Annual Membership meeting in Richmond, Virginia. The new directors will begin their terms effective on January 1, 2018.
Venture capitalists poured $1.55 billion into D.C. area technology start-ups last year, an industry report found, as a handful of so-called megadeals propelled the region to a six-year high for technology investing in 2017.
Personal Genome Diagnostics, a Baltimore-based cancer diagnostics company, has raised $75 million to expand access to genomic testing for cancer patients.